Bayer's Pipeline Momentum Meets the Analyst Split: 61 Euros Versus 46

Bayer shares climbed 3.9% to 45.65 euros on Monday, powered by a pair of pharmaceutical announcements that gave investors fresh reason to look past the conglomerate's recent troubles. The advance of 3.6% cited by dpa-AFX had a concrete foundation: Chinese regulators approved the company's stroke prevention drug, while encouraging prostate cancer data added a second leg to the story.

At the center of the clinical news is Nubeqa, whose active ingredient darolutamide was tested in the Phase III DASL-HiCaP trial in combination with androgen deprivation therapy and radiotherapy. After a median follow-up of 3.8 years, the regimen cut the risk of metastases or death by 58% compared with placebo in prostate cancer patients at high risk of recurrence. Bayer is quick to point out that darolutamide has not yet been approved for this particular treatment setting, leaving the commercial upside tied to further regulatory steps.

A First-in-Class Approval in China

On the cardiovascular side, China's NMPA granted marketing authorization to Asundexian under the brand name Sunharbo. The drug is indicated for reducing stroke risk in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Bayer describes it as the world's first approved Factor XIa inhibitor, a milestone backed by the Phase III OCEANIC-STROKE study. The decision strengthens the company's position in a strategically important Asian growth market.

A third thread runs through the pipeline: the FDA accepted a supplemental application for Finerenone on October 8, covering adults with chronic kidney disease without diabetes. That filing rests on positive results from the Phase III FIND-CKD trial. Acceptance, however, is not approval — a distinction that matters when weighing how much of Bayer's future revenue is already locked in.

Should investors sell immediately? Or is it worth buying Bayer?

Two Houses, Two Verdicts

Wall Street's reaction laid bare the divide over how much credit these advances deserve. JPMorgan's Richard Vosser reaffirmed an "Overweight" rating and a 61-euro price target, taking a positive view of the DASL-HiCaP data. Media reports suggest JPMorgan and a second research house see additional peak sales potential of up to one billion euros from Nubeqa — a projection, not reported revenue and not a confirmed company forecast.

Jefferies' Michael Leuchten struck a more cautious tone. He called the darolutamide efficacy promising but framed it as confirmation of what was already known rather than a fundamental shift. His firm kept Bayer at "Hold" with a 46-euro target, well below JPMorgan's. The gap between the two judgments illustrates a broader point: medical progress and added shareholder value are not the same thing.

What November 3 Will and Won't Settle

The next hard data point arrives on November 3, 2026, when Bayer publishes third-quarter 2026 results. Those figures should sharpen the picture of earnings power and revenue trends across the group's divisions, particularly after the pharma unit's research wins injected some positive momentum. What they will not do is confirm the commercial payoff of Monday's approval — regulatory success establishes a prerequisite for sales, not the sales themselves.

For investors, the takeaway hinges on execution. Optimists are betting that clinical benefit and approval progress will translate into growing business; skeptics want more evidence before repricing the stock. The breadth of Bayer's pipeline — Asundexian in China, darolutamide in prostate cancer, Finerenone in kidney disease — offers multiple shots on goal, but each sits at a different stage of development and carries a different degree of economic certainty. Building expectations faster than the company delivers results raises the risk of disappointment, a tension the November update may begin to resolve.

Ad

Bayer Stock: New Analysis - 26 October

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...